Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses

Table 1 Relevance of potential factors predicting idiotype vaccine-induced clinical outcome in major clinical trials

No. of patients	Comparison	Type of study	Results	Ref.
136	FcγRIIIa 158	Retrospective analysis	Better outcome for V/V	[24,25]
289	FcγRIIIa 158	Prospective analysis	No outcome difference	[38]
117	Idiotype/Isotype	Retrospective analysis	Better outcome for IgM	[23]

FcγRIIIa: Fc γ receptor IIIa; V/V: Valine/valine.

Table 2 Overview of randomized clinical trials addressing the clinical benefit of idiotypic vaccination in patients with follicular lymphoma

Pre-treatment	Pre-vax status	Random	Endpoint	Results	Ref.
6-8 × PACE q 3w	CR	2:01	DFS	Better outcome if vaccinated	[34,35]
8 × CVP q 3w	CR, PR	2:01	PFS	No difference	[38]
4 × rituximab q 1w	CR, PR, SD	1:01	TTP	No difference	[39]

PACE: Cyclophosphamide, doxorubicin, etoposide and prednisone; q 3w: 1 cycle every 3 wk; CR: Complete response; DFS: Disease-free survival; CVP: Cyclophosphamide, vincristine, prednisone; PR: Partial response; PFS: Progression-free survival; q 1w: 1 dose weekly; SD: Stable disease; TTP: Time to progression.